JP2006523440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523440A5 JP2006523440A5 JP2006504100A JP2006504100A JP2006523440A5 JP 2006523440 A5 JP2006523440 A5 JP 2006523440A5 JP 2006504100 A JP2006504100 A JP 2006504100A JP 2006504100 A JP2006504100 A JP 2006504100A JP 2006523440 A5 JP2006523440 A5 JP 2006523440A5
- Authority
- JP
- Japan
- Prior art keywords
- hfe2a
- polypeptide
- isolated polynucleotide
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 76
- 101000756823 Homo sapiens Hemojuvelin Proteins 0.000 claims description 57
- 201000000386 hemochromatosis type 2A Diseases 0.000 claims description 55
- 102100022816 Hemojuvelin Human genes 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 22
- 108700008625 Reporter Genes Proteins 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims 48
- 108091033319 polynucleotide Proteins 0.000 claims 33
- 102000040430 polynucleotide Human genes 0.000 claims 33
- 239000002157 polynucleotide Substances 0.000 claims 33
- 210000004027 cell Anatomy 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 239000007857 degradation product Substances 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 8
- 230000010438 iron metabolism Effects 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 208000016286 Iron metabolism disease Diseases 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 201000000361 Hemochromatosis type 2 Diseases 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000017667 Chronic Disease Diseases 0.000 claims 3
- 208000018565 Hemochromatosis Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 210000004969 inflammatory cell Anatomy 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46286703P | 2003-04-15 | 2003-04-15 | |
| US48860703P | 2003-07-18 | 2003-07-18 | |
| US49845803P | 2003-08-28 | 2003-08-28 | |
| PCT/CA2004/000522 WO2004092405A2 (en) | 2003-04-15 | 2004-04-08 | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523440A JP2006523440A (ja) | 2006-10-19 |
| JP2006523440A5 true JP2006523440A5 (enExample) | 2007-05-24 |
Family
ID=33303911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504100A Pending JP2006523440A (ja) | 2003-04-15 | 2004-04-08 | 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US20070166711A1 (enExample) |
| EP (2) | EP2006298A3 (enExample) |
| JP (1) | JP2006523440A (enExample) |
| AU (2) | AU2004231122B2 (enExample) |
| CA (1) | CA2522680A1 (enExample) |
| WO (1) | WO2004092405A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| EP1490108A4 (en) | 2002-04-18 | 2006-08-09 | Gen Hospital Corp | DRAG11 GENERAL FAMILY (DRAGON) |
| CA2522680A1 (en) | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| WO2006008182A1 (en) * | 2004-07-23 | 2006-01-26 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | RGMc MODIFIED TRANSGENIC ANIMALS |
| EP1858541B1 (en) * | 2005-02-16 | 2012-07-25 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency |
| US7534764B2 (en) * | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
| US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
| WO2008079877A2 (en) * | 2006-12-22 | 2008-07-03 | Xenon Pharmaceuticals Inc. | Compositions and methods for the diagnosis and treatment of iron-related disorders |
| MX2009008104A (es) * | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
| US8895002B2 (en) | 2007-04-09 | 2014-11-25 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
| EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| KR101666228B1 (ko) | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| US20100068737A1 (en) * | 2008-09-16 | 2010-03-18 | University Of Tennessee Research Foundation | Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin |
| CN102245626A (zh) | 2008-12-05 | 2011-11-16 | 加利福尼亚大学董事会 | 微型铁调素肽及其使用方法 |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
| MX2012006560A (es) | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| KR102035357B1 (ko) | 2011-01-19 | 2019-10-23 | 페루맥스 파마수티컬스, 인코포레이티드 | 철 항상성을 조절하기 위한 조성물 및 이의 사용 방법 |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| HK1199892A1 (en) | 2011-12-09 | 2015-07-24 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
| ES2664328T3 (es) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Variantes de albúmina |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| RS62633B1 (sr) | 2013-03-15 | 2021-12-31 | Protagonist Therapeutics Inc | Analozi hepcidina i njihove primene |
| SI3143037T1 (sl) | 2014-05-16 | 2021-11-30 | Protagonist Therapeutics, Inc. | Antagonisti integrin alpha4beta7 tioeterskih peptidov |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| EP3240799B1 (en) | 2014-12-29 | 2021-03-31 | The Regents of the University of California | S-alkylated hepcidin peptides and methods of making and using thereof |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2017165676A1 (en) | 2016-03-23 | 2017-09-28 | Protagonist Therapeutics, Inc. | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3045370A1 (en) | 2018-06-08 | 2019-12-08 | Pfizer Inc. | Methods of treating metabolic disease |
| EP3820883A4 (en) | 2018-07-12 | 2022-04-20 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CN116082455A (zh) | 2019-07-10 | 2023-05-09 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| SI4090670T1 (sl) | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni |
| EP4090669A4 (en) | 2020-01-15 | 2024-11-20 | Janssen Biotech, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| IL316550A (en) | 2020-11-20 | 2024-12-01 | Janssen Pharmaceutica Nv | Compositions of interleukin-23 receptor peptide inhibitors |
| IL310061A (en) | 2021-07-14 | 2024-03-01 | Janssen Biotech Inc | Peptide inhibitors linked to fatty residues of the interleukin-23 receptor |
| EP4433160A1 (en) | 2021-11-17 | 2024-09-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
| JP2026506602A (ja) | 2023-02-13 | 2026-02-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 鉄過剰関連疾患の処置方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69532857T2 (de) | 1994-10-27 | 2005-04-28 | Genentech Inc., San Francisco | Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor |
| US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
| US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| JP2003518364A (ja) | 1999-05-28 | 2003-06-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用 |
| US6180353B1 (en) * | 2000-01-24 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense modulation of daxx expression |
| US6800455B2 (en) * | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| EP1355666B1 (en) * | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| EP1368475A4 (en) * | 2001-03-15 | 2004-10-20 | Nuvelo Inc | NEW NUCLEIC ACIDS AND NEW POLYPEPTIDES |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| EP1490108A4 (en) * | 2002-04-18 | 2006-08-09 | Gen Hospital Corp | DRAG11 GENERAL FAMILY (DRAGON) |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| CA2522680A1 (en) * | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| US7534764B2 (en) * | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
-
2004
- 2004-04-08 CA CA002522680A patent/CA2522680A1/en not_active Abandoned
- 2004-04-08 EP EP08154618A patent/EP2006298A3/en not_active Withdrawn
- 2004-04-08 AU AU2004231122A patent/AU2004231122B2/en not_active Ceased
- 2004-04-08 WO PCT/CA2004/000522 patent/WO2004092405A2/en not_active Ceased
- 2004-04-08 JP JP2006504100A patent/JP2006523440A/ja active Pending
- 2004-04-08 EP EP04726398A patent/EP1618131A2/en not_active Withdrawn
- 2004-04-08 US US10/552,158 patent/US20070166711A1/en not_active Abandoned
-
2005
- 2005-08-04 US US11/197,710 patent/US7511018B2/en not_active Expired - Fee Related
-
2009
- 2009-02-09 US US12/322,931 patent/US7893206B2/en not_active Expired - Fee Related
- 2009-06-19 US US12/456,667 patent/US8080651B2/en not_active Expired - Fee Related
- 2009-09-15 US US12/584,947 patent/US20100068803A1/en not_active Abandoned
-
2010
- 2010-06-29 AU AU2010202722A patent/AU2010202722B2/en not_active Ceased
-
2011
- 2011-01-24 US US12/931,068 patent/US8252578B2/en not_active Expired - Fee Related
-
2012
- 2012-07-19 US US13/553,321 patent/US8507435B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523440A5 (enExample) | ||
| Sun et al. | Mosaic mutant analysis identifies PDGFRα/PDGFRβ as negative regulators of adipogenesis | |
| Fusco et al. | Roles of HMGA proteins in cancer | |
| Pegg | Spermidine/spermine-N 1-acetyltransferase: a key metabolic regulator | |
| Ziegler et al. | Insulin-like growth factor II: an essential adult stem cell niche constituent in brain and intestine | |
| Wong et al. | Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling | |
| Li et al. | Nebulin deficiency in adult muscle causes sarcomere defects and muscle-type-dependent changes in trophicity: novel insights in nemaline myopathy | |
| Perry et al. | Complex regulation of acetylcholinesterase gene expression in human brain tumors | |
| Sakata et al. | Mechanical stretch induces TGF‐β synthesis in hepatic stellate cells | |
| Lodyga et al. | XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway | |
| Jinnin et al. | Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1 | |
| CA2353086A1 (en) | Pgc-1, a novel brown fat ppar.gamma. coactivator | |
| Chauvet et al. | Control of gene expression by the retinoic acid-related orphan receptor alpha in HepG2 human hepatoma cells | |
| JP2005522999A5 (enExample) | ||
| Hu et al. | CCAAT/enhancer-binding protein β isoforms and the regulation of α-smooth muscle actin gene expression by IL-1β | |
| Kasprzak et al. | Role of alternatively spliced messenger RNA (mRNA) isoforms of the insulin-like growth factor 1 (IGF1) in selected human tumors | |
| Bosc et al. | Regulation of Her2/neu promoter activity by the ETS transcription factor, ER81 | |
| Chen et al. | Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression | |
| Varco-Merth et al. | Differential effects of STAT proteins on growth hormone-mediated IGF-I gene expression | |
| CN1159585C (zh) | 检测瘦素的方法 | |
| Tanioka et al. | Regulation of the human leukocyte‐derived arginine aminopeptidase endoplasmic reticulum‐aminopeptidase 2 gene by interferon‐γ | |
| Kim et al. | Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation | |
| Jeong et al. | Directed immobilization of DNA-binding proteins on a cognate DNA-modified chip surface | |
| JP2006524491A5 (enExample) | ||
| JP2002523094A5 (enExample) |